Post I made in answer to another:
Your post gets to the gist of the problem IPIX has had to date. To make it BIG, a biotech startup not only needs great science, but great management and the financials to be able to withstand BPs cherry picking their product(s) knowing they need help financially in a big, big, big way. A startup has to have the TOTAL BUSINESS PACKAGE to demand the value for their science that it deserves.
Is IPIX today the TOTAL PACKAGE? HELL NO!!
But are they moving in the right direction, HELL YES!!
IPIX has been moving forward on the science side over the past number of years in bringing forward both Brilacidin and Kevetrin but sadly put a great deal into Prurisol that didn't pan out.
So was Prurisol an error with which we should beat mgt over the head? HELL NO!! Biotech startup is about as risky as it gets and though Prurisol looked like it should be a great drug sadly that did not prove to be the case. No chance for success if you don't try.
What it did do was put IPIX in a hole as to funds available for B and to finish the K pill. Then IPIX seemed to have a partnership for OM and the partner changed mgt and the incoming execs decided to table the deal. Such is business, but IPIX still in a pickle as to being able to raise funds without heavy dilution. Speaking of dilution, many (me included) have felt there has been a strong case of those trying to tank IPIX share price just so such dilution would have to occur and possible put IPIX into BK. So again, I don't give mgt any great kudos for financial raisings over the last few years but sometimes the best laid plans just lay there like a steaming pile.
Keep in mind during this time mgt has been constantly ravaged by posters, their business plan scoffed at, and their modest advances on any front put down as "fluff" whenever a PR was issued and mgt was "keeping things from stockholders" when a PR didn't come out. Hard to win against this type of daily derision and counter productive measures. Disclaimers had a field day because they knew that IPIX couldn't assemble the TOTAL PACKAGE.
But what has changed since last Fall, because since then IPIX is RAPIDLY BECOMING THE TOTAL PACKAGE.
They hired Locust Walk so we now have a professional team handling negotiations.
OM was OK'd by FDA to proceed to a P3.
They established a presence in Ireland to be able to have clinical trials proceed in the EU and in the long run save on taxes. EU medical overseer OK'd a P3 OM trial.
IBD pill was formulated and a GREAT delivery system was developed to be able to put it right in the correct spot of the colon where needed. This was shown by a successful proof of concept trial.
IBD scheduled to start a P2 for Ulcerative Colitis this summer.
That brings us to about Feb 2020.
THEN CV19 HIT AND THE IPIX TOTAL PACKAGE STARTED ITS WAY TO CRITICAL MASS.
What began as what many thought was simply a way to get more publicity for Brilacidin and free investigative research paid for by the US government started.
At that time, the hope was that Brilacidin would show some effect on the severe respiratory problems being incurred (and causing the vast majority of deaths) of CV patients with a slight possibility of becoming a treatment for same.
Then the profile of Bs anti-viral properties came to light and it was realized that it interfered in almost all the pathways CV used to invade the body.
Govt research highlighted that it could attach to the CV virus and it's ability to prevent pro-inflammatory cytokines and chemokines (natural body defensins) which was also killing many patients.
Then through the computerized analysis of 20K drugs Brilacidin was found to be among only a HANDFUL of products that could attack CV and the ONLY PRODUCT that had the 3-in-1 properties of being anti-viral, inflammatory, and bacterial).
Brilacidin now is in the top 5 or so drugs being tested for CV and may be the ONLY one being tested as both a treatment and a vaccine (or a vaccine adjuvant to be part of a vaccine cocktail).
It is being tested at a Level 3 biology lab, a RBL, and one or two universities.
AND ALL OF THE ABOVE TESTING IS AT GOVERNMENT EXPENSE.
I think we are 2 steps away from being able to say we have the GOLDEN RING for CV in Brilacidin; passing the current lung tissue test and doing well in human trials. Does Brilacidin have to be successful in both areas of treatment and vaccine? NO, but it would sure help the world and the science as we know it now says it has a very good chance of succeeding in both areas.
So let's everybody get off IPIX's ass about past years when they were in the big leagues using minor league financing and begging for a seat at the biotech table and concentrate on what is happening TODAY - THAT OF IPIX CHANGING INTO A POSSIBLE BIOTECH DYNAMO BEFORE OUR VERY EYES.
Last question - What BPs with a dated portfolio of patented drugs wouldn't love to exchange same for the arsenal that Brilacidin and Kevetrin seem to be bringing to the table? A little ways to go to get to this point, but the CRITICAL MASS is pulling in funding, eyeballs, and worldwide exposure!!!
Your post gets to the gist of the problem IPIX has had to date. To make it BIG, a biotech startup not only needs great science, but great management and the financials to be able to withstand BPs cherry picking their product(s) knowing they need help financially in a big, big, big way. A startup has to have the TOTAL BUSINESS PACKAGE to demand the value for their science that it deserves.
Is IPIX today the TOTAL PACKAGE? HELL NO!!
But are they moving in the right direction, HELL YES!!
IPIX has been moving forward on the science side over the past number of years in bringing forward both Brilacidin and Kevetrin but sadly put a great deal into Prurisol that didn't pan out.
So was Prurisol an error with which we should beat mgt over the head? HELL NO!! Biotech startup is about as risky as it gets and though Prurisol looked like it should be a great drug sadly that did not prove to be the case. No chance for success if you don't try.
What it did do was put IPIX in a hole as to funds available for B and to finish the K pill. Then IPIX seemed to have a partnership for OM and the partner changed mgt and the incoming execs decided to table the deal. Such is business, but IPIX still in a pickle as to being able to raise funds without heavy dilution. Speaking of dilution, many (me included) have felt there has been a strong case of those trying to tank IPIX share price just so such dilution would have to occur and possible put IPIX into BK. So again, I don't give mgt any great kudos for financial raisings over the last few years but sometimes the best laid plans just lay there like a steaming pile.
Keep in mind during this time mgt has been constantly ravaged by posters, their business plan scoffed at, and their modest advances on any front put down as "fluff" whenever a PR was issued and mgt was "keeping things from stockholders" when a PR didn't come out. Hard to win against this type of daily derision and counter productive measures. Disclaimers had a field day because they knew that IPIX couldn't assemble the TOTAL PACKAGE.
But what has changed since last Fall, because since then IPIX is RAPIDLY BECOMING THE TOTAL PACKAGE.
They hired Locust Walk so we now have a professional team handling negotiations.
OM was OK'd by FDA to proceed to a P3.
They established a presence in Ireland to be able to have clinical trials proceed in the EU and in the long run save on taxes. EU medical overseer OK'd a P3 OM trial.
IBD pill was formulated and a GREAT delivery system was developed to be able to put it right in the correct spot of the colon where needed. This was shown by a successful proof of concept trial.
IBD scheduled to start a P2 for Ulcerative Colitis this summer.
That brings us to about Feb 2020.
THEN CV19 HIT AND THE IPIX TOTAL PACKAGE STARTED ITS WAY TO CRITICAL MASS.
What began as what many thought was simply a way to get more publicity for Brilacidin and free investigative research paid for by the US government started.
At that time, the hope was that Brilacidin would show some effect on the severe respiratory problems being incurred (and causing the vast majority of deaths) of CV patients with a slight possibility of becoming a treatment for same.
Then the profile of Bs anti-viral properties came to light and it was realized that it interfered in almost all the pathways CV used to invade the body.
Govt research highlighted that it could attach to the CV virus and it's ability to prevent pro-inflammatory cytokines and chemokines (natural body defensins) which was also killing many patients.
Then through the computerized analysis of 20K drugs Brilacidin was found to be among only a HANDFUL of products that could attack CV and the ONLY PRODUCT that had the 3-in-1 properties of being anti-viral, inflammatory, and bacterial).
Brilacidin now is in the top 5 or so drugs being tested for CV and may be the ONLY one being tested as both a treatment and a vaccine (or a vaccine adjuvant to be part of a vaccine cocktail).
It is being tested at a Level 3 biology lab, a RBL, and one or two universities.
AND ALL OF THE ABOVE TESTING IS AT GOVERNMENT EXPENSE.
I think we are 2 steps away from being able to say we have the GOLDEN RING for CV in Brilacidin; passing the current lung tissue test and doing well in human trials. Does Brilacidin have to be successful in both areas of treatment and vaccine? NO, but it would sure help the world and the science as we know it now says it has a very good chance of succeeding in both areas.
So let's everybody get off IPIX's ass about past years when they were in the big leagues using minor league financing and begging for a seat at the biotech table and concentrate on what is happening TODAY - THAT OF IPIX CHANGING INTO A POSSIBLE BIOTECH DYNAMO BEFORE OUR VERY EYES.
Last question - What BPs with a dated portfolio of patented drugs wouldn't love to exchange same for the arsenal that Brilacidin and Kevetrin seem to be bringing to the table? A little ways to go to get to this point, but the CRITICAL MASS is pulling in funding, eyeballs, and worldwide exposure!!!
11
